Synopsis
Vaxxas is a biotech company developing an innovative method to deliver vaccines using a high-density microarray patch (HD-MAP), which is applied to the skin for a few seconds rather than being injected with a needle. This technology has the potential to significantly enhance the efficiency and accessibility of vaccinations worldwide.
HD-MAP utilises a micro-needling technology that painlessly delivers the vaccine through the skin and has the potential to be self-administered, reducing the need for trained medical professionals. The HD-MAP also eliminates the risk of needle-stick injuries and the need for cold storage, making vaccines more stable and easier to transport.
This technology could vastly improve the speed and efficiency of vaccination campaigns, positively impacting public health by preventing the spread of deadly diseases. It could also help increase vaccination rates, particularly in hard-to-reach populations, ultimately saving hundreds of thousands of lives each year.
testimonials
David Hoey
Strategic Advisor, Founding CEO Vaxxas
OneVentures have been terrific to work with as a lead investor, but it’s what they add in addition to investment that has been critical to Vaxxas’ growth.
Working with the OneVentures team has translated into sharpening all aspects of our development and commercialisation strategy and actively helped us forge connections and partners with industry.
